Flupenthixol versus risperidone: subjective quality of life as an important factor for compliance in chronic schizophrenic patients.

Hertling, I; Philipp, M; Dvorak, A; Glaser, T; Mast, O; Beneke, M; Ramskogler, K; Saletu-Zyhlarz, G; Walter, H; Lesch, O M

Hertling, I; Philipp, M; Dvorak, A; Glaser, T; Mast, O; Beneke, M; Ramskogler, K; Saletu-Zyhlarz, G; Walter, H; Lesch, O M.

Affiliation

Hertling I; Department of Psychiatry, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Neuropsychobiology ; 47(1): 37-46, 2003.

Article in En | MEDLINE | ID: mdl-12606844

Subject(s)

Antipsychotic Agents/therapeutic use; Flupenthixol/therapeutic use; Quality of Life; Risperidone/therapeutic use; Schizophrenia/drug therapy; Schizophrenic Psychology; Adolescent; Adult; Aged; Attitude to Health; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Psychiatric Status Rating Scales; Surveys and Questionnaires; Treatment Outcome

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Schizophrenia / Schizophrenic Psychology / Antipsychotic Agents / Risperidone / Flupenthixol Type of study: Clinical_trials Aspects: Patient_preference Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Neuropsychobiology Year: 2003 Document type: Article Affiliation country: Austria Country of publication: Switzerland

Search on Google

Add to My VHL

XML

PubMed Links